x
Ariana Pharma
[contact-form-7 404 "Not Found"]

Ariana Pharma
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News & more
    • In The News
    • Case study
    • Publications
      • Publications & Conferences
      • Whitepaper & blog
  • Careers
Logo

Contact Info

  • 58-60 Avenue de la Grande Armée, 75017, Paris, France
  • +33 1 44 37 17 00
  • info@arianapharma.com

Author: Thomas Turcat

Recent Posts

Sep2024

Passing of Dr. Mohammad Afshar, Founder of Ariana Pharma

It is with profound sadness that we announce the passing of our founder, CEO and Chairman, Dr. Mohammad Afshar, on August 8th, 2024.
Dr. Afshar was a visionary leader, as well as a physician, researcher, entrepreneur, and pioneer in the field of AI and healthcare.

Read More
Precision Medicine

May2024

Ariana is 20… we’ve come a long way

Cast your mind back to when Ariana was founded… Facebook was just launching, Data Scientist had yet to be declared “the sexiest job of the 21st century,” and AI was nowhere near as widespread as today. I vividly recall a potential client asking me, “Why do you do this? This is data torture!”  We talked […]

Read More
Cancer Precision Medicine Recent Posts

Apr2024

Ariana Pharma announces important Artificial Intelligence (AI) collaboration in precision oncology to accelerate a first-in class antibody blocking lipid metabolism for the treatment of advanced cancer

Artificial Intelligence and organoid data to accelerate the development of a first-in-class antibody in precision oncology. Paris, France and Cambridge, MA, USA, 16th April, 2024, Ariana Pharma, a leading Artificial Intelligence drug development company, announced today that it has entered a €3 million consortium sponsored by the Eurostars 3 program, led by ONA Therapeutics SL, […]

Read More
Precision Medicine Recent Posts

Mar2024

Ariana Pharma Announces Major Artificial Intelligence Collaboration in Cell Therapy with Leading Academic Partners Targeting Immune Regulatory T Cells

Explainable Artificial Intelligence and multi-modal clinical and omic investigations in immunotherapy applied to organ transplantation.  Paris, France and Cambridge, MA, USA, March 1st, 2024. Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered a $10 million funded Artificial Intelligence-driven Cell Therapy collaboration with Assistance Publique – Hôpitaux de Paris (AP-HP), […]

Read More
Recent Posts Cancer

May2023

Ariana Pharma continues to bolster Scientific Advisory Board by adding world-leading Oncologist Pr. Jean-Yves BLAY

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological […]

Read More
Recent Posts

Mar2023

Ariana Pharma strengthens SAB with appointment of world-leading Neurologist Jacques Touchon

Cambridge, MA, USA and Paris, France, March 27, 2023 – Ariana Pharma, the leading Al-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.

Read More
Alzheimer's

Nov2022

CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ​

• Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
• CY6463 favorable tolerability and safety profile was confirmed

Read More
Parkinson’s

Oct2022

Parkinson’s Disease: A new path toward restoring key neurodegenerative functions. Discover our analysis of a clinical trial highlighting a potential molecular mechanism of blarcamesine! (ANAVEX®2-73)

Parkinson’s Disease: A new path toward restoring key neurodegenerative functions. Discover our analysis of a clinical trial highlighting a potential molecular mechanism of blarcamesine! (ANAVEX®2-73) Blarcamesine significantly restores functionality in key molecular pathways including Alzheimer’s and Parkinson’s disease, KEM® xAI analysis shows. Cambridge, MA, USA and Paris, France – Ariana Pharma, the leading Al-driven precision medicine company, […]

Read More
Recent Posts

Jul2022

Ariana Pharma strengthens management team with appointments of VP Business Development and Chief Financial Officer

Paris, France and Cambridge, MA, USA, July 26th, 2022 – Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. […]

Read More

Categories

  • Alzheimer's
  • Autism
  • Autoimmune disease
  • Cancer
  • Fibromyalgia
  • Kidney Transplant
  • Parkinson’s
  • Precision Medicine
  • Publications
  • Real World Evidence
  • Recent Posts
  • Type A Diabetes

Tags

alzheimer's autism cancer Event Fibromyalgia Graft rejection Influenza Kidney Laboratory lung neurological Oncology Professor Jean-Yves BLAY Centre Leon berard Parkinson Parkinson’s precisionmedicine precision medicine publication realworldevidence recent post Recent Posts Research Transplant vaccine

Ariana Pharmaceuticals, The AI DRUG Development Company

  • Paris, FRANCE / Cambridge, MA, USA
  • Call Us: +33 144 37 17 00
  • info@arianapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Ariana Pharma © 2024 All Rights Reserved